Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) commenced an underwritten public offering of ordinary shares and, for certain investors, pre-funded warrants to purchase ordinary shares. All securities in the proposed transaction will be offered by Crescent, and the company plans to grant underwriters a 30‑day option to buy up to an additional 15% of the ordinary shares at the public offering price, less underwriting discounts and commissions.

The offering is being made under an effective shelf registration statement on Form S‑3 declared effective on July 10, 2026 and remains subject to market and other conditions, with no assurance on timing, size, or completion. Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book‑running managers, with LifeSci Capital as passive book‑running manager.

Positive

• None.

Negative

• Proposed equity and pre‑funded warrant sale may dilute existing shareholders; actual size not yet disclosed

News Explained

No offering size or price is disclosed yet; completed sales would add company cash and potentially reduce existing holders’ percentage ownership.

On July 14, 2026, Crescent Biopharma commenced a proposed offering in which the company would sell ordinary shares or pre-funded warrants; if completed, cash would go to Crescent and newly issued shares, including shares from exercised warrants, could reduce existing holders’ percentage ownership.

The release provides no offering size, price, fees, or expected proceeds and says completion, timing, and terms remain subject to market and other conditions.

An effective Form S-3 provides registration capacity for future sales rather than recording a sale; pre-funded warrants convert into shares when exercised, and the prospectus supplement is the filing expected to state the offering’s final size, price, and fees.

At March 31, 2026, Crescent reported $189.163 million of cash and equivalents and first-quarter operating cash outflow of $8.937 million; that cash equals 1905 days of the last reported operating cash use, but the undisclosed offering size cannot yet be compared with the cash balance on a committed-dollar basis.

The preliminary prospectus supplement and subsequent final terms filing are the specific documents to watch for the amount raised and the number of shares or warrants issued, which will establish the transaction’s actual dilution and proceeds.

Sources and calculations

• Crescent Biopharma proposed public offering release (2026-07-14)
• Dilution definition (undated)
• Pre-funded warrant definition (undated)
• Form S-3 purpose (undated)
• Prospectus supplement purpose (undated)
• Crescent Biopharma first-quarter 2026 fundamentals (2026Q1)

• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $189,163,000 / ($8,937,000 / 90) = [object Object]

News Market Reaction – CBIO

+2.38% 4.7x vol

6 alerts

+2.38% Session close to close

+7.2% Peak in 17 hr 29 min

$478.15M Market Cap

4.7x Rel. Volume

In the Jul 15 session, CBIO gained 2.38%, reflecting a moderate positive market reaction. Argus tracked a peak move of +7.2% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.7x the daily average, suggesting strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Viewed alongside an active S-3 shelf allowing up to $500,000,000 of securities and a $200,000,000 op...

Analysis

Viewed alongside an active S-3 shelf allowing up to $500,000,000 of securities and a $200,000,000 open market sale agreement, this offering fits a broader capital-raising framework; with net insider selling and moderate short interest, investors may watch for further shelf usage or additional offerings.

Key Figures

Underwriter option period: 30 days Overallotment size: 15% of ordinary shares Shelf effectiveness date: July 10, 2026

3 metrics

Underwriter option period 30 days Duration of option to purchase additional ordinary shares

Overallotment size 15% of ordinary shares Maximum additional shares underwriters may purchase at offering price

Shelf effectiveness date July 10, 2026 Form S-3 shelf registration statement declared effective by SEC

Historical Context

5 past events · Latest: Jun 26 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 26	Inducement awards	Negative	-3.0%	Grant of stock options as equity inducement awards to non-executive employees.
Jun 11	Inducement awards	Positive	+0.6%	Additional stock option inducement grants to non-executive employees with 10-year term.
Jun 02	Investor conferences	Positive	+5.7%	Announcement of June 2026 presentations at major healthcare investor conferences.
May 29	Inducement awards	Negative	-4.5%	Inducement stock options covering 16,950 shares with 10-year term and vesting schedule.
May 21	Clinical trial update	Positive	+2.5%	Planned Trial-in-Progress poster for ASCEND Phase 1/2 study at ASCO 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news for CBIO has produced mixed reactions, with both positive and negative single-day moves following announcements.

Key Terms

pre-funded warrants, underwritten public offering, shelf registration statement, form s-3, +2 more

6 terms

pre-funded warrants financial

"in lieu of ordinary shares to investors that so choose, pre-funded warrants to purchase its ordinary shares."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten public offering financial

"announced that it has commenced an underwritten public offering of its ordinary shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"pursuant to a shelf registration statement on Form S-3, including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

book-running managers financial

"Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers"

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has commenced an underwritten public offering of its ordinary shares or, in lieu of ordinary shares to investors that so choose, pre-funded warrants to purchase its ordinary shares. In addition, Crescent intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares at the public offering price, less underwriting discounts and commissions. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering are being offered by Crescent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Jefferies, TD Cowen, Guggenheim Securities and Cantor are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as passive book-running manager for the proposed offering.

The securities described above are being offered by Crescent pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (“SEC”) and was declared effective on July 10, 2026. A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus can be accessed through the SEC’s website at www.sec.gov. Copies of the prospectus supplement relating to the proposed offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors.

Forward-Looking Statements

Crescent cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the completion, timing and size of the proposed offering, and the grant of the option to purchase additional ordinary shares. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, our quarterly report on Form 10-Q for the quarter ended March 31, 2026, and any subsequent current reports on Form 8-K or other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

What did Crescent Biopharma (CBIO) announce on July 14, 2026?

Crescent Biopharma announced it commenced an underwritten public offering of ordinary shares and pre‑funded warrants. According to Crescent, all securities are being sold by the company, with an additional 15% over‑allotment option for underwriters, subject to market and other conditions.

What securities are included in Crescent Biopharma’s proposed CBIO offering?

The proposed CBIO offering includes ordinary shares and, in lieu of shares for some investors, pre‑funded warrants. According to Crescent, all offered ordinary shares and pre‑funded warrants will be issued by the company under an effective shelf registration statement on Form S‑3.

How large is the Crescent Biopharma (CBIO) public offering announced in July 2026?

Crescent has not disclosed the total size or pricing of the CBIO offering. According to Crescent, underwriters are expected to receive a 30‑day option to purchase up to an additional 15% of ordinary shares, but overall terms remain subject to market conditions.

Who are the underwriters for Crescent Biopharma’s CBIO share and warrant offering?

Jefferies, TD Cowen, Guggenheim Securities and Cantor are joint book‑running managers, with LifeSci Capital as passive book‑running manager. According to Crescent, these firms will manage the proposed underwritten offering of ordinary shares and pre‑funded warrants under the effective shelf registration.

What registration statement covers Crescent Biopharma’s July 2026 CBIO offering?

The CBIO offering is being made under a shelf registration statement on Form S‑3, including a base prospectus. According to Crescent, this registration statement was previously filed with the SEC and declared effective on July 10, 2026, enabling the proposed securities sale.

How can investors obtain the preliminary prospectus for Crescent Biopharma’s CBIO offering?

Investors can access the preliminary prospectus supplement and prospectus via the SEC’s website at www.sec.gov. According to Crescent, copies may also be requested from Jefferies, TD Securities, Guggenheim Securities, Cantor, or LifeSci Capital through their listed addresses, phone numbers, or emails.